Pyrazinamide 500 mg Tablets Recalled for Quality Program Discontinuation
RemedyRepack Inc. is recalling Pyrazinamide 500 mg tablets because the original manufacturer discontinued the quality assurance program that would ensure the product meets identity, strength, quality, and purity standards.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses or deaths. The recall addresses a manufacturing quality assurance program discontinuation, representing a theoretical risk rather than a confirmed product defect or contamination.
Plain-English summary
RemedyRepack Inc., located in Pennsylvania, is recalling Pyrazinamide 500 mg tablets in two packaging formats: 29 x 30-count cards (NDC 70518-2534-01, Lot B2110254-021423, expiration 08/17/2023) and 100-count unit-dose boxes (NDC 70518-2534-00, Lot J0684183-022323, expiration 02/28/2024). The product was originally manufactured by Akorn in Lake Forest, Illinois, and repackaged by RemedyRepack.
The recall was initiated because the original manufacturer discontinued the quality assurance program that would ensure the product meets its identity, strength, quality, and purity characteristics. This represents a manufacturing deviation from FDA Current Good Manufacturing Practice (CGMP) requirements.
The affected product was distributed to three direct customer accounts in Pennsylvania. Patients currently taking this medication should consult with their healthcare provider or pharmacist before discontinuing use. Healthcare providers and patients with this product should stop dispensing or using it and contact RemedyRepack Inc. or their pharmacy for instructions on returning the product or obtaining replacement medication from another source.
The recalled product
- Product
- Pyrazinamide, 500 mg Tablet, packaged in a) 29 x 30-count card, NDC # 70518-2534-01; b) 1 x 100 UD box, NDC # 70518-2534-00, MFG: Akorn, Lake Forest, IL 60045, Repackaged by : RemedyRepack Inc., PA 15701. Mfg NDC # 61748-0012-01
- Manufacturer
- RemedyRepack Inc.
- Category
- Drug
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot: a) B2110254-021423
- exp. date 08/17/2023
- b) J0684183-022323
- exp. date 02/28/2024
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 3 recalled by RemedyRepack Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · RemedyRepack Inc.
See all →- ModerateClindamycin HCl Capsule 300 mg repackaged by RemedyRePack Inc.
FDA (Drugs) · 2025-05-14
- ModerateClindamycin HCl 300 mg Capsule Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-30
- HighCarvedilol 25 mg tablets recalled due to N-nitroso impurity above limit
FDA (Drugs) · 2025-02-12
- HighDuloxetine delayed-release capsules recalled due to manufacturing impurity
FDA (Drugs) · 2025-01-01
- HighPotassium Chloride Extended Release Capsules Recalled for Dissolution Defect
FDA (Drugs) · 2024-07-24
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19